Jane Henderson
CIK 1422304 · Chief Financial Officer · last filed 2026-07-24
Jane Henderson is a Chief Financial Officer who has filed 63 SEC Form 4 insider transactions across 10 companies since 2008. The most recent filing, for APGE, was dated Jul 24, 2026. Across all open-market trades the lifetime net is −$5.7M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $21.3M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$21.25M
10
63
-$5.70M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| APGE | Chief Financial Officer | 158,371 | $134.19 | $21.25M | -$2.38M | 16 | 2026-07-24 |
| Akero Therapeutics, Inc. (AKRO) Delisted | Director | 0 | $54.65 | $0 | -$2.31M | 9 | 2025-12-09 |
| CARGO Therapeutics, Inc. (CRGX) Delisted | Director | — | $4.47 | — | $0 | 3 | 2025-08-19 |
| IVERIC bio, Inc. (ISEE) Delisted | Director | 22,088 | $39.95 | $882.4K | $0 | 6 | 2023-05-19 |
| Invivyd, Inc. (ADGI) Delisted | Chief Financial Officer | — | $4.64 | — | $0 | 1 | 2022-02-01 |
| Carisma Therapeutics Inc. (SESN) Delisted | Director | — | $12.58 | — | $0 | 4 | 2021-05-10 |
| IVERIC bio, Inc. (OPHT) Delisted | Director | — | — | — | $0 | 2 | 2018-07-11 |
| VYGR | Sr. V.P. & CFO, Corp. Dev. | 0 | $3.03 | $0 | -$1.03M | 4 | 2018-03-26 |
| Carisma Therapeutics Inc. (EBIO) Delisted | Director | — | — | — | $0 | 3 | 2017-05-23 |
| PANACOS PHARMACEUTICALS, INC. (PANC) Delisted | Chief Financial Officer & CBO | 125,000 | — | — | $23.5K | 3 | 2008-05-05 |
Recent Filings
63 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-24 | APGE | Gift (G) | −15,000 | $0 | EDGAR |
| 2026-05-04 | APGE | Sell (S) | −2,000 | -$164.1K | EDGAR |
| 2026-05-01 | APGE | Notice (144) | −2,000 | -$165.8K | EDGAR |
| 2026-04-17 | APGE | Sell (S) | −2,000 | -$180.0K | EDGAR |
| 2026-04-03 | APGE | Sell (S) | −2,000 | -$170.0K | EDGAR |
| 2026-03-27 | APGE | Sell (S) | −2,000 | -$170.0K | EDGAR |
| 2026-03-25 | APGE | Notice (144) | −6,000 | -$438.0K | EDGAR |
| 2026-03-04 | APGE | Sell (S) | −2,000 | -$140.4K | EDGAR |
| 2026-02-04 | APGE | Sell (S) | −2,000 | -$131.6K | EDGAR |
| 2026-01-06 | APGE | Mixed | −8,000 | -$609.1K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.